Should I Buy QSI? QSI 2026 Analysis

Should You Buy Quantum-Si Inc (QSI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.060

1 Day change

14.27%

52 Week Range

3.100

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

QSI is not a good buy right now for an impatient investor. The stock is in a confirmed downtrend (bearish moving averages, weakening MACD), forward pattern stats also skew negative over the next day/week, and fundamentals show shrinking revenue and deteriorating gross margin. Options positioning is call-heavy (bullish sentiment), but without a catalyst, that looks more like speculative positioning than a reliable reversal signal. With increased insider selling and no proprietary buy signals today, the risk/reward is unfavorable for an immediate entry.

Technical Analysis

Price/Trend: QSI at $1.13 (-2.56% regular session) remains in a bearish structure with SMA_200 > SMA_20 > SMA_5, signaling a sustained downtrend. Momentum: MACD histogram is negative (-0.00265) and negatively expanding, implying downside momentum is strengthening rather than stabilizing. RSI: RSI_6 at ~31.9 is near oversold but still not showing a clear reversal trigger; “near oversold” alone is not enough to buy aggressively in a strong downtrend. Levels: Pivot 1.223 is overhead (price below pivot = bearish). Immediate support zone is S1 1.143 (already below/around this area) and S2 1.094; a clean break below ~1.09 would further confirm weakness. Resistance levels to reclaim are 1.223 then 1.304. Pattern/near-term bias: Similar-pattern projection indicates a 70% probability of further downside: -1.56% next day, -1.47% next week, -0.46% next month.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment/Positioning: Put-call ratios are extremely low (OI PCR 0.19; Volume PCR 0.08), indicating strong call skew and bullish/speculative sentiment. Volatility: Implied volatility is very elevated (30D IV ~~205%) vs historical volatility (~~125%), with IV percentile ~77. This implies options are expensive and the market is pricing large moves. Flow/Activity: Today’s option volume is ~2,960 with calls dominating (2,735 calls vs 225 puts). This supports bullish positioning, but in a downtrend it can also reflect short-dated speculation rather than informed accumulation. Net takeaway: Options sentiment is bullish, but it conflicts with the bearish trend and weak fundamentals; without a catalyst, call-skew alone is not a high-conviction buy signal.

Technical Summary

Sell

Buy

Positive Catalysts

Potential product/pipeline upside: Coverage notes suggest pipeline remains on track and a focus shift toward the Proteus launch could become a positive catalyst if milestones or adoption exceed expectations.
Sector backdrop: One analyst expects life science tools momentum to continue into 2026, which could provide a better macro tape for the group if funding conditions improve.
Call-heavy options positioning: The market is positioned for upside tails (very low put/call ratios), which could amplify a rebound if a positive catalyst hits.

Neutral/Negative Catalysts

Downtrend momentum: Bearish moving-average stack plus worsening MACD suggests sellers remain in control.
Insider behavior: Insiders are selling, with selling amount up ~110.92% over the last month—this is a meaningful negative signal for near-term confidence.
Funding overhang: Commentary highlights weaker NIH funding and government shutdown impacts, reducing near-term demand visibility for life science tools.
No recent news: Lack of fresh catalysts in the past week reduces the probability of an abrupt sentiment shift.
Pattern-based outlook: Similar-pattern statistics skew to continued mild downside over the next day/week/month.

Financial Performance

Latest quarter (2025/Q3):

Revenue: $552K, down 29.86% YoY (clear top-line contraction).
Net income: -$35.70M, improved 41.05% YoY (loss narrowed, but still deeply negative).
EPS: -$0.17, down 5.56% YoY (earnings still deteriorated slightly on a per-share basis).
Gross margin: 35.14%, down 24.64% YoY (margin compression is a key negative, suggesting weaker unit economics/scale). Growth read: The company is not showing durable growth yet—revenue and margin trends are moving the wrong direction, which makes it hard to justify an impatient buy without a clear upcoming catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Price targets are being cut.

2025-12-22 Canaccord: PT lowered to $1.50 from $2; rating Hold.
2025-11-07 Alliance Global Partners: PT lowered to $2.50 from $3; rating Buy. Wall Street pros: Long-term pipeline/launch potential (Proteus) and potential sector momentum into 2026. Wall Street cons: Near-term demand headwinds (NIH funding/government shutdown), unimpressive recent revenue, and enough uncertainty that at least one firm remains at Hold while cutting PT. Influential/political trading: No recent Congress trading data available; hedge funds noted as neutral.

3 Analyst Rating

Wall Street analysts forecast QSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QSI is 2.67 USD with a low forecast of 1.5 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.932

Low

1.5

Averages

2.67

High

Current: 0.932

Low

1.5

Averages

2.67

High

Canaccord

Hold

downgrade

AI Analysis

2025-12-22

Reason

Canaccord

Price Target

AI Analysis

2025-12-22

downgrade

Hold

Reason

Canaccord lowered the firm's price target on Quantum-Si to $1.50 from $2 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026.

Alliance Global Partners

Scott Henry

Buy

downgrade

2025-11-07

Reason

Alliance Global Partners

Scott Henry

Price Target

2025-11-07

downgrade

Buy

Reason

Alliance Global Partners analyst Scott Henry lowered the firm's price target on Quantum-Si to $2.50 from $3 and keeps a Buy rating on the shares. The firm notes Quantum-Si reported Q3 earnings that were within expectations. Alliance Global highlights that quarterly revenue was within expectations, although unimpressive due to the overhang from lower NIH funding, and it appears that the government shutdown is making this environment even worse, which reduces the potential for a near-term rebound. The firm lowered its forecasts meaningfully to reflect a focus shift towards the Proteus launch given this backdrop, but notes the pipeline remains on track and supports its long-term positive investment thesis.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QSI

Unlock Now

QSI Should I Buy

QSI Should I Buy

Should You Buy Quantum-Si Inc (QSI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch